Mineralys Therapeutics, Inc. Common Stock (MLYS) — Net Asset Momentum
Mineralys Therapeutics, Inc. Common Stock (MLYS) recorded a net asset momentum of 238.1% as of December 2025, with net assets of $646.69 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See defensive interval ratio of Mineralys Therapeutics, Inc. Common Stoc to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Mineralys Therapeutics, Inc. Common Stock Net Asset Momentum (2020–2025)
This chart tracks Mineralys Therapeutics, Inc. Common Stock's year-over-year net asset growth across 6 annual reporting periods from 2020 to 2025. The most recent momentum reading is +238.1%, with net assets of $646.69 Million USD as of December 2025. Read MLYS total debt and obligations for a breakdown of total debt and financial obligations.
Annual Net Asset History for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the complete annual net asset history for Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025, covering 6 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see Mineralys Therapeutics, Inc. Common Stoc stock valuation.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $646.69 Million | $661.81 Million | $15.11 Million | ▲ +238.1% |
| 2024 | $191.26 Million | $205.90 Million | $14.65 Million | ▼ -20.7% |
| 2023 | $241.15 Million | $251.64 Million | $10.48 Million | ▲ +561.4% |
| 2022 | $-52.27 Million | $114.44 Million | $166.71 Million | ▼ -128.0% |
| 2021 | $-22.93 Million | $11.12 Million | $34.05 Million | ▼ -537.3% |
| 2020 | $-3.60 Million | $1.49 Million | $5.08 Million | — |